Journal
ALZHEIMER DISEASE & ASSOCIATED DISORDERS
Volume 25, Issue 1, Pages 73-84Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/WAD.0b013e3181f5b8d8
Keywords
random forest; biomarker; fluorodeoxyglucose positron-emission tomography; volumetric MRI; cerebrospinal fluid
Categories
Funding
- Abbott
- National Institutes of Health
- AstraZeneca AB
- Bayer Schering Pharma AG
- Bristol-Myers Squibb
- Eisai Global Clinical Development
- Elan Corporation
- Genentech
- GE Healthcare
- GlaxoSmithKline
- Innogenetics
- Johnson Johnson
- Eli Lilly and Co.
- Merck and Co., Inc.
- Novartis AG
- Pfizer Inc.
- F. Hoffmann-La Roche
- Schering-Plough
- Synarc Inc.
- Wyeth
- Alzheimer Association
- Institute for the Study of Aging
Ask authors/readers for more resources
Model-based statistical approaches were used to compare the ability of the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog), cerebrospinal fluid (CSF), fluorodeoxyglucose positron emission tomography and volumetric magnetic resonance imaging (MRI) markers to predict 12-month progression from mild cognitive impairment (MCI) to Alzheimer disease (AD). Using the Alzheimer's Disease Neuroimaging Initiative (ADNI) data set, properties of the 11-item ADAS-cog (ADAS. 11), the 13-item ADAS-cog (ADAS. All) and novel composite scores were compared, using weighting schemes derived from the Random Forests (RF) tree-based multivariate model. Weighting subscores using the RF model of ADAS. All enhanced discrimination between elderly controls, MCI and AD patients. The ability of the RF-weighted ADAS-cog composite and individual scores, along with neuroimaging or biochemical biomarkers to predict MCI to AD conversion over 12 months was also assessed. Although originally optimized to discriminate across diagnostic categories, the ADAS. All, weighted according to the RF model, did nearly as well or better than individual or composite baseline neuroimaging or CSF biomarkers in prediction of 12-month conversion from MCI to AD. These suggest that a modified subscore weighting scheme applied to the 13-item ADAS-cog is comparable to imaging or CSF markers in prediction of conversion from MCI to AD at 12 months.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available